Skip to content
value.today

Goodwin Biotechnology, Inc

Total raised
$31 M
4 rounds on record
Latest round
$2 M
Dec 2025
First round on record
Apr 2019
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Goodwin Biotechnology, Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2025$2 MNo. 4$2 to $10 million

Goodwin Biotechnology, Inc: Raise no. 4, Dec 2025

Investors in this round

2 investors had bought by the notice of Jan 27, 2026: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $4 M offered; $2 M still to sell
Smallest investment taken
$1,000,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
  • Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Karl Pinto · Executive Officer, Director
  • Steven Vorgity · Executive Officer
  • Brandon Price · Director
  • Divya Menezes · Director
  • Kent Payne · Director
  • Nikhil Puri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Karl Pinto, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 27, 2026. Read the notice at the SEC.

debt, optionsSEC
Nov 2024$3 MNo. 3$2 to $10 million

Goodwin Biotechnology, Inc: Raise no. 3, Nov 2024

Investors in this round

1 investor had bought by the notice of Nov 12, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$3,000,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
  • Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Karl Pinto · Executive Officer, Director
  • Steven Vorgity · Executive Officer
  • Brandon Price · Director
  • Divya Menezes · Director
  • Kent Payne · Director
  • Nikhil Puri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Karl Pinto, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 12, 2024. Read the notice at the SEC.

debt, optionsSEC
Sep 2023$5 MNo. 2$2 to $10 million

Goodwin Biotechnology, Inc: Raise no. 2, Sep 2023

Investors in this round

3 investors had bought by the notice of Oct 2, 2023: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
$522,500
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
  • Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Darrin Schellin · Executive Officer, Director
  • Steven Vorgity · Executive Officer
  • Brandon Price · Director
  • Divya Menezes · Director
  • Karl Pinto · Director
  • Kent Payne · Director
  • Nikhil Puri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Darrin Schellin, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 2, 2023. Read the notice at the SEC.

equity, optionsSEC
Apr 2019$21 MNo. 1$10 to $50 million

Goodwin Biotechnology, Inc: Raise no. 1, Apr 2019

Investors in this round

5 investors had bought by the notice of Apr 30, 2019: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$600,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Karl Pinto · Executive Officer, Director · Chief Executive Officer and President
  • SooYoung S. Lee · Executive Officer · Chief Operating Officer and Secretary
  • Sunil K. Agarwal · Executive Officer · Financial Controller and Treasurer
  • Cesar K. Menezes · Director
  • Divya K. Menezes · Director
  • Jerry Emila Liao · Director
  • Maria Emila Menezes · Director
  • Nikhil Emila Puri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Fairmount Partners LP (CRD 146668) · broker-dealer Cornelius P. McCarthy III (CRD 2153332) · West Conshohocken, PennsylvaniaSold in NY, PA

Signed by Sunil K. Agarwal, Financial Controller. Source: SEC Form D, newest notice filed Apr 30, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Goodwin Biotechnology, Inc chose not to state its revenue in its newest notice of a funding round (Jan 2026).

    SEC Form D · Jan 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2026

That is all the official record says: Goodwin Biotechnology, Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Goodwin Biotechnology, Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 5 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Goodwin Biotechnology, Inc
NameRoleNamed in
Karl PintoExecutive officerJan 2026
Steven VorgityExecutive officerJan 2026
Darrin SchellinExecutive officerOct 2023
SooYoung S. LeeChief Operating Officer and SecretaryApr 2019
Sunil K. AgarwalFinancial Controller and TreasurerApr 2019
Brandon PriceDirectorJan 2026
Divya MenezesDirectorJan 2026
Karl PintoDirectorJan 2026
Kent PayneDirectorJan 2026
Nikhil PuriDirectorJan 2026
Darrin SchellinDirectorOct 2023
Cesar K. MenezesDirectorApr 2019
Divya K. MenezesDirectorApr 2019
Jerry Emila LiaoDirectorApr 2019
Maria Emila MenezesDirectorApr 2019
Nikhil Emila PuriDirectorApr 2019